Trial data likely to be positive for Afrezza, but cautiion still warranted: Cowen • 10:11 AM

• Highly anticipated data due this month from Affinity Phase 1/2 trials has a "fairly high chance of being positive," Cowen's Simos Simeonidis thinks.
• Investors may be wise to exercise caution however, as Afrezza approval is far from certain and MannKind (MNKD -4.8%) would also likely need a commercial partner.
• Shares are rated Market Perform.